Response to Levrier re: Human Germline and Heritable Genome Editing: The Global Policy Landscape
By Marcy Darnovsky, Katie Hasson, and Timothy M. Krahn,
The CRISPR Journal
| 02. 19. 2021
In response to: https://www.liebertpub.com/doi/10.1089/crispr.2021.29121.gle
Levrier apparently misunderstands the nature of our project published in The CRISPR Journal in October 2020.1 We identified and reviewed policy documents relevant to human germline and heritable genome editing research in 96 countries. We did not speculate about arguments that might lead legislatures or courts to revise existing policies or adjudicate prospective cases, nor did we attempt to examine each policy in its national or international context. Rather, based on close and careful readings of the identified texts, we categorized countries according to the current permissibility or impermissibility of germline and heritable genome editing. Then, we counted.
We welcome corrections and additions to the data we have compiled, which we plan to keep updated at https://tinyurl.com/HumanGenomeEditingPolicies. Unfortunately, Levrier does not provide appropriate documentation for his challenge to our categorizations regarding human germline and heritable genome editing research in three countries (France, Mexico, and Japan). Instead, he points to a report, unspecified “debates” in the French parliament, and comments on social media. We sometimes used such sources to identify relevant policy documents, but did...
Related Articles
Not the species, certainly, but the Institute of that name, which was founded by transhumanist philosopher Nick Bostrom in 2005 as a research group at Oxford University. According to a recently posted Final Report, its goal was “to pursue the big questions in a transdisciplinary way” by pulling together “researchers from disciplines such as philosophy, computer science, mathematics, and economics.” This evolved before long into the study and promotion of “effective altruism” and “longtermism” as...
By Yelena Biberman and Jonathan D. Moreno, Bioethics Forum | 04.16.2024
A quiet biological revolution in warfare is underway. The genome is emerging as a new domain of conflict. The level of destruction that only nuclear weapons could previously achieve is fast becoming as accessible as a cyberattack.
Now for the...
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...